<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A6AC6319-D273-43EB-909C-FB31FDFBFC16"><gtr:id>A6AC6319-D273-43EB-909C-FB31FDFBFC16</gtr:id><gtr:name>Barts Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>William Harvey Research Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A6AC6319-D273-43EB-909C-FB31FDFBFC16"><gtr:id>A6AC6319-D273-43EB-909C-FB31FDFBFC16</gtr:id><gtr:name>Barts Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EE07BD70-8447-4C4E-92EC-A1111EFA165B"><gtr:id>EE07BD70-8447-4C4E-92EC-A1111EFA165B</gtr:id><gtr:firstName>Federica</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Marelli-Berg</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901084"><gtr:id>5E7F5825-7B0D-4915-A3AD-FB124524D67B</gtr:id><gtr:title>Programming memory T cell homing to target immunization strategies.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901084</gtr:grantReference><gtr:abstractText>Targeting activated T lymphocytes to the site of pathogen invasion could greatly enhance the effectiveness of conventional vaccination protocols. We have devised a novel strategy to target the topographic distribution of memory T lymphocytes following vaccination. Specifically, we have observed that T cell priming in the presence of tissue-specific factors (particularly chemokines) favors the development of specific T cells with homing preference for the tissue, and therefore seek to fully establish the molecular mechanisms of this novel protocol of immunization and its potential application in clinical settings. Our preliminary studies and the forward experiments proposed will provide the opportunity for new therapeutic vaccination designs in the short-term. Besides its relevance to highly prevalent human gut infections (such as those induced by parasitic infection), this model will pave the way for the application of similar strategies to organ-selective targeting of T cell immunity in a range of diseases, including cancer.</gtr:abstractText><gtr:technicalSummary>The design of conventional immunization strategies has mainly focused on improving the magnitude and duration of memory T cell responses. Besides these important parameters, selective localization of primed T cells to sites of antigenic re-challenge is paramount for rapid and protective recall responses. Following priming, T cells acquire the ability to establish molecular interactions mediated by tissue-selective adhesion and chemokine receptors (homing receptors) that direct them to specific organs, thus allowing them to ?remember? the site where pathogen invasion has originally occurred. Thus, imprinting T cells with an ?area code? of the site where pathogen invasion is likely to re-occur will greatly enhance the development of rapid, protective immunity. We have recently designed a novel immunization protocol in which T cell activation in the presence of gut-derived chemotactic factors (CCL25) favors the development of memory T cells that express gut-homing receptors and selectively localize to gut-asssociated lymphoid tissue and gut tissue when adoptively transferred in vivo. We propose to fully investigate this novel protocol of immunization with the aim to achieve topographic immunological memory leading to targeted, faster and more effective recall responses. Besides the potential in the control of gut infections, we provide evidence that tissue-selective immunization can be achieved in a variety of other tissues (including humans), and propose that this protocol can be applied in human organ-specific infectious diseases other than those affecting the gut.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>608072</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Hannover Medical School (MHH)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>role of CCR9 in gut T cell immunity</gtr:description><gtr:id>AE997711-1594-4BE3-9D78-C55A56F9F75E</gtr:id><gtr:impact>control experiments needed for a publication</gtr:impact><gtr:partnerContribution>CCR9KO mice</gtr:partnerContribution><gtr:piContribution>authorship on a publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>T cell homing in pancreatic ductal adenocarcinoma (PDAC)</gtr:description><gtr:id>4BF64060-913A-4673-8628-482DF78C4B11</gtr:id><gtr:impact>1. Data will be included in a manuscript in preparation
2. The possibility of filing a patent application is currently considered by our IP team</gtr:impact><gtr:partnerContribution>Provided an orthotopic PDAC model</gtr:partnerContribution><gtr:piContribution>We show that cancer vaccination with CCL25 improves anti-tumour immunity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Intestinal nematode infestation in CCL25KO mice</gtr:description><gtr:id>04056FB3-144D-4F27-BD94-37C0E3FFA280</gtr:id><gtr:impact>The data will be included in a manuscript in preparation.</gtr:impact><gtr:partnerContribution>Performed experiments and provided data</gtr:partnerContribution><gtr:piContribution>We provided CCL25KO mice and experimental design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visit to GSK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5AC2D009-7570-480C-8D35-48E9DC77C05B</gtr:id><gtr:impact>Discussion of potential areas of investment by GSK in my institution</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Grand Challenge Exploration Phase II award</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>995BBC25-2337-4957-8385-DA666C7B598A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Grand Challenge Exploration Phase I award</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>0DAD8767-2AD0-46F2-BF0C-32C933CDD4CB</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>439131</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Multi-user Equipment Grant</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>WT 063308</gtr:fundingRef><gtr:id>0DDFF9E7-C4FD-4045-A74F-0E2E131179F7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP7 EU COFUND</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>AAB375A0-DB2F-4852-9AB5-CB03FDCFA36C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method for preventing cardiac graft rejection or a method for preventing and/or treating a T-cell mediated heart disease in a subject by administering a Hepatocyte Growth Factor (HGF) receptor inhibitor to the subject</gtr:description><gtr:id>3753DE51-112E-441F-9A32-0D6ECB65362F</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>GB1316878.6</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>The present invention relates to a method for preventing cardiac graft rejection or a method for preventing and/or treating a T-cell mediated heart disease in a subject by administering a Hepatocyte Growth Factor (HGF) receptor inhibitor to the subject</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIH NIAMS Centers of Research Translation (CORT)</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>352BC8D6-8273-406B-B1B6-142DD953712C</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of a guideline committee - ANR - &amp;quot;Immunology and Infectious Diseases - CES 15&amp;quot; (2016)</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>99D0BA95-19BF-4328-87A9-3B8386927F13</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Deutsche Forschungsgemeinschaft (DFG) review committee on Collaborative Research Centre (Sonderforschungsbereich) - CRC914/2</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>BFE0BDE4-FA47-4BF0-89F7-05F85DA0870D</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Deutsche Forschungsgemeinschaft (DFG) review committee on Collaborative Research Centre (Sonderforschungsbereich) - CRC 1009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>A9133B29-E0D9-4E97-AABB-B4D83E8BC41F</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Deutsche Forschungsgemeinschaft (DFG) review committee on Collaborative Research Centre (Sonderforschungsbereich) - Munich</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9652898E-9E63-4947-B69D-FB806349D762</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ANR - &amp;quot;Immunology and Infectious Diseases - CES 15&amp;quot;</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>3036D00C-7C52-4A75-A9D1-D76554855019</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Deutsche Forschungsgemeinschaft (DFG) review committee on Collaborative Research Centre (Sonderforschungsbereich) - CRC 1009/2</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>DAFDBD11-D942-4538-BCC1-F9E3B03D78D9</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Review panel MH-E1: Cardiovascular and Urogenital diseases, Transplantation and diseases of haematogenous organs at the Swedish Research Council</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>D72DBF49-7095-4261-8D98-2116A5F0D4F1</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transplant of human tissue in SKID Beige Mice and T cell recirculation through the graft</gtr:description><gtr:id>18B6C945-D33B-4724-9673-DEC602D3406C</gtr:id><gtr:impact>Publication: Komarowska, I., D. Coe, G. Wang, R. Haas, C. Mauro, M. Kishore, D. Cooper, S. Nadkarni, H. Fu, D.A. Steinbruchel, C. Pitzalis, G. Anderson, P. Bucy, G. Lombardi, R. Breckenridge, and F. M. Marelli-Berg. 2015. c-Met signals instruct T cell cardiotropism and facilitate T lymphocyte recruitment to the heart by inducing autocrine chemokine release. Immunity, 42:1087-99</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Humanised model of T cell trafficking</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D980FCE6-3B79-4DE1-B88D-7654020C42DE"><gtr:id>D980FCE6-3B79-4DE1-B88D-7654020C42DE</gtr:id><gtr:title>Memory T-cell trafficking: new directions for busy commuters.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78bc001b023b0d17345a4d0196e3218f"><gtr:id>78bc001b023b0d17345a4d0196e3218f</gtr:id><gtr:otherNames>Marelli-Berg FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA1B317F-AFAF-4AE4-B593-97CF74C0175A"><gtr:id>EA1B317F-AFAF-4AE4-B593-97CF74C0175A</gtr:id><gtr:title>Applying an adaptive watershed to the tissue cell quantification during T-cell migration and embryonic development.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/25befd1fbfccea14e32520047fbe60a7"><gtr:id>25befd1fbfccea14e32520047fbe60a7</gtr:id><gtr:otherNames>Zhu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0FC17E1-FBEC-474D-B48E-0AF101C576D6"><gtr:id>F0FC17E1-FBEC-474D-B48E-0AF101C576D6</gtr:id><gtr:title>In the eye of the storm: T cell behavior in the inflammatory microenvironment.</gtr:title><gtr:parentPublicationTitle>American journal of clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f93fd1188aab7703a9e0f87e71de2cb"><gtr:id>6f93fd1188aab7703a9e0f87e71de2cb</gtr:id><gtr:otherNames>Haas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DAB06FA-7652-49B1-846E-387B16404B8E"><gtr:id>8DAB06FA-7652-49B1-846E-387B16404B8E</gtr:id><gtr:title>Rac activation by the T-cell receptor inhibits T cell migration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4dfc47badcf8fad57024ac7e4ab912b6"><gtr:id>4dfc47badcf8fad57024ac7e4ab912b6</gtr:id><gtr:otherNames>Cernuda-Moroll?n E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E330A02E-1ABD-4BE4-93DD-025BDDA43975"><gtr:id>E330A02E-1ABD-4BE4-93DD-025BDDA43975</gtr:id><gtr:title>Tracking antigen-experienced effector T cells in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/10fce4304e9802d28dcf5bb978a74a95"><gtr:id>10fce4304e9802d28dcf5bb978a74a95</gtr:id><gtr:otherNames>Gorman CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B5729350-ECA8-4422-8AA8-BC7C598CC5F7"><gtr:id>B5729350-ECA8-4422-8AA8-BC7C598CC5F7</gtr:id><gtr:title>Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d6a7ee0f691937e2d7656b89816d236"><gtr:id>3d6a7ee0f691937e2d7656b89816d236</gtr:id><gtr:otherNames>Komarowska I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4CD3B44-DA50-4D3B-8E00-9B6C49FD5D60"><gtr:id>D4CD3B44-DA50-4D3B-8E00-9B6C49FD5D60</gtr:id><gtr:title>Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f93fd1188aab7703a9e0f87e71de2cb"><gtr:id>6f93fd1188aab7703a9e0f87e71de2cb</gtr:id><gtr:otherNames>Haas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6383AD6F-9190-4CCF-8207-FE86D8BF7A48"><gtr:id>6383AD6F-9190-4CCF-8207-FE86D8BF7A48</gtr:id><gtr:title>T lymphocyte trafficking: molecules and mechanisms.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Landmark edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb9606206151d22b19e9270d672f5575"><gtr:id>bb9606206151d22b19e9270d672f5575</gtr:id><gtr:otherNames>Fu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1093-4715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9110B8E-B05D-477A-B3AF-A287DD887BFD"><gtr:id>A9110B8E-B05D-477A-B3AF-A287DD887BFD</gtr:id><gtr:title>Mechanisms of T cell organotropism.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb9606206151d22b19e9270d672f5575"><gtr:id>bb9606206151d22b19e9270d672f5575</gtr:id><gtr:otherNames>Fu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE6FFAFC-1E6C-4BC2-A498-CBAC64AD92D9"><gtr:id>EE6FFAFC-1E6C-4BC2-A498-CBAC64AD92D9</gtr:id><gtr:title>Enhanced and aberrant T cell trafficking following total body irradiation: a gateway to graft-versus-host disease?</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c9a1b3d0bc55e06ade5b2c73544881a6"><gtr:id>c9a1b3d0bc55e06ade5b2c73544881a6</gtr:id><gtr:otherNames>Vianello F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901084</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>